Robert M Lorence

Summary

Publications

  1. ncbi request reprint Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
    Andrew L Pecora
    Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    J Clin Oncol 20:2251-66. 2002
  2. ncbi request reprint Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
    Robert M Lorence
    Wellstat Biologics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Curr Opin Mol Ther 5:618-24. 2003
  3. ncbi request reprint Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
    Robert M Lorence
    Wellstat Biologics Corporation, Gaithersburg, MD 20878, USA
    Curr Cancer Drug Targets 7:157-67. 2007
  4. ncbi request reprint Naturally oncolytic viruses
    M Scot Roberts
    Wellstat Biologics Corp, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Curr Opin Mol Ther 8:314-21. 2006
  5. ncbi request reprint Naturally occurring viruses for the treatment of cancer
    M Scot Roberts
    Wellstat Biologics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Discov Med 6:217-22. 2006
  6. ncbi request reprint A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
    Scott A Laurie
    Division of Medical Oncology and Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
    Clin Cancer Res 12:2555-62. 2006
  7. ncbi request reprint An optimized clinical regimen for the oncolytic virus PV701
    Sebastien J Hotte
    Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada
    Clin Cancer Res 13:977-85. 2007

Detail Information

Publications7

  1. ncbi request reprint Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
    Andrew L Pecora
    Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    J Clin Oncol 20:2251-66. 2002
    ..This phase I study was designed to define the maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer...
  2. ncbi request reprint Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
    Robert M Lorence
    Wellstat Biologics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Curr Opin Mol Ther 5:618-24. 2003
    ..Phase II studies are planned...
  3. ncbi request reprint Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
    Robert M Lorence
    Wellstat Biologics Corporation, Gaithersburg, MD 20878, USA
    Curr Cancer Drug Targets 7:157-67. 2007
    ..In addition, patient tolerability improved using the Hamilton Regimen compared to IV bolus dosing used previously. Phase 2 studies of this novel biologic agent are about to begin...
  4. ncbi request reprint Naturally oncolytic viruses
    M Scot Roberts
    Wellstat Biologics Corp, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Curr Opin Mol Ther 8:314-21. 2006
    ..In this review, the mechanism of selectivity as well as the preclinical and clinical activity of naturally oncolytic viruses will be discussed...
  5. ncbi request reprint Naturally occurring viruses for the treatment of cancer
    M Scot Roberts
    Wellstat Biologics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Discov Med 6:217-22. 2006
    ..These viruses have the potential to specifically target tumor cells, and insights into the molecular mechanisms of this selectivity are beginning to emerge...
  6. ncbi request reprint A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
    Scott A Laurie
    Division of Medical Oncology and Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
    Clin Cancer Res 12:2555-62. 2006
    ..This study tested the hypothesis that two-step desensitization, using two dose increments before high repeat doses, would be well tolerated...
  7. ncbi request reprint An optimized clinical regimen for the oncolytic virus PV701
    Sebastien J Hotte
    Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada
    Clin Cancer Res 13:977-85. 2007
    ..v. infusion rate, and that this approach would allow for the safe administration of higher doses. Additionally, this phase 1 trial was the first to measure PV701 clearance...